1. Scrip
  2. >>Business

BMS Opts In On Exscientia’s AI-Designed Immune-Modulating Candidate

Bristol Myers Squibb Will Handle Compound’s Clinical, Commercial Development

 
• By Sten Stovall

Bristol Myers Squibb will in-license an immune-modulating drug candidate created by AI-pioneer Exscientia, the first in their expanded multi-target alliance announced in May.

AI-designed drug is first in duo's multi-target collaboration to reach in-license milestone • Source: Alamy

AI pioneer Exscientia Ltd. has generated the first novel drug candidate in its $1.2bn partnership with Bristol Myers Squibb Company– that being an immune-modulating compound, for which the nine-year-old spinout drug discovery group will get $20m from BMS for the early exploration work.

The in-licensed candidate targets a critical immunological kinase that has “historically proven difficult to target” due to the need for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Ever The Outlier, Biotech Outpaces Broader Stocks

 
• By Mandy Jackson

Public Company Edition: The US jobs report for August hurt the S&P 500 and Dow Jones, but the XBI rose 2.2% and is up 6% year-to-date. Despite signs of life, with a recent small IPO from Curanex and a larger one proposed by LB Pharmaceuticals, fundraising was down in Q2.

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart

 
• By Joseph Haas

Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

What’s Next For OMass After Roche Licensing Deal

 
• By Manas Mishra

OMass Therapeutics has signed its debut licensing deal with Roche’s Genentech unit. Its CEO Rosamond Deegan talked to Scrip about what drew Roche’s interest to the preclinical IBD program, the company’s lead assets and the potential for other deals.

More from Scrip

Executives On The Move: New CEO At Mitsubishi Tanabe Pharma

Recent moves in the industry include C-suite changes at Mitsubishi Tanabe Pharma and Oculis Holding, plus clock.bio gets a new chief business officer from BioNTech.

Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia

 
• By Mandy Jackson

Approval in alpha- and beta-thalassemia by a Sept. 7 action date seemed assured, but an FDA review of proposed REMS regarding potential liver injury pushed it back to Dec. 7.

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

 
• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.